Metabolic syndrome and cardiovascular risk prediction in peripheral arterial disease

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 9, 2010, Pages 676-682

  Brevetti, G ^a   Laurenzano, E ^a   Giugliano, G ^a   Lanero, S ^a   Brevetti, L ^a   Luciano, R ^a   Chiariello, M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Ankle brachial index; Intermittent claudication; Risk factors

Indexed keywords

AGED; ANKLE BRACHIAL INDEX; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; KAPLAN MEIER METHOD; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; WAIST CIRCUMFERENCE;

AGED; ANKLE BRACHIAL INDEX; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; KAPLAN-MEIER ESTIMATE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 78049409741     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.05.016     Document Type: Article

References (31)

1. Kahn R., Buse J., Ferrannini E., Stern M. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
2. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
3. Alberti K.G., Zimmet P., Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet 2005, 366:1059-1062.
4. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. J Am Med Assoc 2002, 287:356-359.
5. Cameron A.J., Shaw J.E., Zimmet P.Z. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004, 33:351-375.
6. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002, 288:2709-2716.
7. Scuteri A., Najjar S.S., Morrell C.H., Lakatta E.G. Cardiovascular Health Study. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 2005, 28:882-887.
8. Girman C.J., Rhodes T., Mercuri M., Pyörälä K., Kjekshus J., Pedersen T.R., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93:136-141.
9. Stern M.P., Williams K., Hunt K.J. Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl 2005, 6:3-6.
10. Wassink A.M., van der Graaf Y., Olijhoek J.K., Visseren F.L. SMART Study Group. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2008, 29:213-223.
11. Weitz J.I., Byrne J., Clagett G.P., Farkouh M.E., Porter J.M., Sackett D.L., et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996, 94:3026-3049.
12. Olijhoek J.K., van der Graaf Y., Banga J.D., Algra A., Rabelink T.J., Visseren F.L. The SMART Study Group. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004, 25:342-348.
13. Brevetti G., Schiano V., Sirico G., Giugliano G., Laurenzano E., Chiariello M. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg 2006, 44:101-107.
14. Steg P.G., Bhatt D.L., Wilson P.W., D'Agostino R., Ohman E.M., Röther J., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. J Am Med Assoc 2007, 297:1197-1206.
15. Newman A.B., Shemanski L., Manolio T.A., Cushman M., Mittelmark M., Polak J.F., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999, 19:538-545.
16. Heagerty P.J., Lumley T., Pepe M.S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000, 56:337-344.
17. Efron B., Tibshirani R.J. An introduction to the bootstrap 1993, Chapman & Hall, London, UK.
18. Pepe M.S., Janes H., Longton G., Leisenring W., Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159:882-890.
19. Miccoli R., Bianchi C., Odoguardi L., Penno G., Caricato F., Giovannitti M.G., et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 2005, 15:250-254.
20. Wild S.H., Byrne C.D., Tzoulaki I., Lee A.J., Rumley A., Lowe G.D., et al. Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: The Edinburgh Artery Study. Atherosclerosis 2009, 203:604-609.
21. Golledge J., Leicht A., Crowther R.G., Clancy P., Spinks W.L., Quigley F. Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication. J Vasc Surg 2007, 45:40-46.
22. De Simone G., Devereux R.B., Chinali M., Roman M.J., Lee E.T., Resnick H.E., et al. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the strong heart study. Nutr Metab Cardiovasc Dis 2009, 19:98-104.
23. Esposito K., Ciotola M., Carleo D., Schisano B., Saccomanno F., Sasso F.C., et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006, 29:1071-1076.
24. Esposito K., Giugliano D. The metabolic syndrome and inflammation: association or causation?. Nutr Metab Cardiovasc Dis 2004, 14:228-232.
25. Brevetti G., Silvestro A., Schiano V., Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003, 108:2093-2098.
26. Brevetti G., Schiano V., Laurenzano E., Giugliano G., Petretta M., Scopacasa F., et al. Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur Heart J 2008, 29:224-230.
27. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. J Am Med Assoc 2004, 292:1440-1446.
28. Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992, 326:381-386.
29. Robbins D.C., Andersen L., Bowsher R., Chance R., Dinesen B., Frank B., et al. Report of the American Diabetes Association's Task Force on standardization of the insulin assay. Diabetes 1996, 45:242-256.
30. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
31. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.